![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Piscitelli S.C.
Publisher: Adis International
ISSN: 0114-5916
Source: Drug Safety, Vol.22, Iss.1, 2000-01, pp. : 19-31
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
A Risk-Benefit Assessment of HIV Protease Inhibitors
Drug Safety, Vol. 20, Iss. 4, 1999-04 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
A Risk-Benefit Assessment of Metformin in Type 2 Diabetes Mellitus
Drug Safety, Vol. 20, Iss. 6, 1999-06 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Risk–benefit effects of tocolytic therapy
By Pryde Peter G Janeczek Susan Mittendorf Robert
Expert Opinion on Drug Safety, Vol. 3, Iss. 6, 2004-11 ,pp. :